DGI:ZNS-Infektionen/Anmerkung der Redaktion

1.       Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 2;302(21):2323-9

2.       Kumta N, Roberts JA, Lipman J et al. Antibiotic distribution into cerebrospinal fluid: Can dosing safely account for drug and disease factors in the treatment of ventriculostomy-associated infections? Clin Pharmacokinet 2018; 57: 439–454

3.       Bassmann U, Roehr AC, Frey OR, Vetter-Kerkhoff C, Thon N, Hope W, Briegel J, Huge V. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Crit Care 2016; 20: 343

4.       Conen A, Fux CA, Vajkoczy P, Trampuz A. Management of infections associated with neurosurgical implanted devices. Expert Rev Anti Infect Ther 2017;15(3): 241-255

5.      Nau R et al. S1-Leitlinie Hirnabszess. 2016. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien

6.       Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, van de Beek D, Bleck TB, Garton HJL, Zunt JR. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017; 64: e34–e65

7.      Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. https://www.awmf.org/leitlinien/detail/ll/082-006.html

1.         Schaberg, T., et al., [Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie, 2017. 71(6): p. 325-397.

2.         Wilkinson, R.J., et al., Tuberculous meningitis. Nat Rev Neurol, 2017. 13(10): p. 581-598.

3.         Ducomble, T., et al., The burden of extrapulmonary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to 2009. Euro Surveill, 2013. 18(12).

4.         in Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. 2011: London.

5.         Thwaites, G., et al., British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect, 2009. 59(3): p. 167-87.

6.         Marais, S., et al., Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis, 2013. 56(3): p. 450-60.

7.         Chin, J.H., Tuberculous meningitis: Diagnostic and therapeutic challenges. Neurol Clin Pract, 2014. 4(3): p. 199-205.

8.         Marais, S., et al., Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis, 2010. 10(11): p. 803-12.

9.         Amagon, K.I., O. Awodele, and A.J. Akindele, Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients. Pharmacol Res Perspect, 2017. 5(5).

10.       Prasad, K. and M.B. Singh, Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev, 2008(1): p. CD002244.

11.       Thwaites, G.E., et al., Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med, 2004. 351(17): p. 1741-51.